(Q35737399)

10 August 2017

1 reference

title

Regional chemotherapeutic techniques for liver tumors: current knowledge and future directions (English)

1 reference

10 August 2017

1 reference

Dominique Elias

1

1 reference

10 August 2017

Thierry de Baere

series ordinal

2

1 reference

10 August 2017

Lucas Sideris

series ordinal

3

1 reference

10 August 2017

Michel Ducreux

series ordinal

4

1 reference

10 August 2017

publication date

1 April 2004

1 reference

Surgical Clinics of North America

10 August 2017

published in

1 reference

10 August 2017

volume

84

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

607-625

1 reference

A systematic overview of chemotherapy effects in colorectal cancer

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Laparoscopic placement of hepatic artery catheter for regional chemotherapy infusion: technique, benefits, and complications.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Complications and technical limitations of hepatic arterial infusion catheter placement for chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Liver intraarterial chemotherapy: use of the femoral artery for percutaneous implantation of catheter-port systems

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Radiologic placement of side-hole catheter with tip fixation for hepatic arterial infusion chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Combined regional and systemic chemotherapy by a mini-invasive approach for the treatment of colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Implantable hepatic arterial infusion device: placement without laparotomy via an intercostal artery

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Intrahepatic chemotherapy with floxuridine, leucovorin and dexamethasone in continuous infusion and mitomycin-C bolus in unresectable hepatic metastases from colorectal cancer: a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Hepatic arterial infusion using pirarubicin combined with systemic chemotherapy: a phase II study in patients with nonresectable liver metastases from colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Previous intravenous chemotherapy does not alter response rate or survival time of patients with hepatic metastases from colorectal cancer treated by hepatic artery chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Case report: Hepatic arterial occlusion following infusion catheter placement: recanalization using the Palmaz stent

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant hepatic arterial infusion chemotherapy after curative resection of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Intra-arterial iodine 131-labeled lipiodol as adjuvant therapy after curative liver resection for hepatocellular carcinoma: a phase 2 clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Noradrenaline improves the tumour to normal blood flow ratio and drug delivery in a model of liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Somatostatin receptor gene therapy combined with targeted therapy with radiolabeled octreotide: a new treatment for liver metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

Adjuvant intraportal chemotherapy for Dukes B2 and C colorectal cancer also receiving systemic treatment: results of a multicenter randomized trial. Groupe Régional d'Etude du Cancer Colo-Rectal (Belgium)

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2803%2900225-1

7 January 2021

10.1016/S0039-6109(03)00225-1

Identifiers

DOI

1 reference

10 August 2017

1 reference